GenTAC Aortic Summit 2024
The Chairs of the GenTAC Aortic Summit 2024 are pleased to share our meeting program.
Our mission is to share the current knowledge of the scientific underpinnings of genetic aortic disease, to review current best practices related to diagnosis and treatment, and to foster scientific and educational exchange between scientists, institutions, lay organizations and others interested in genetic aortic conditions. Each session will have a combination of invited speakers and interesting debates.
Session Topics
In addition to the oral presentations and debates, we encourage abstract submissions for poster
presentation from students, early career scientists as well as experienced clinicians and scientists. We welcome abstracts utilizing mouse models advancing our understanding of HTAD as well as clinical studies.
Topics can include but are not limited to the following:
- Biomarkers of Aneurysm and Dissection (Imaging or Other Types)
- Sexual Differences in HTAD, perspectives in management and outcomes
- Studies investigating pregnancy, post-partum complications
- Studies in Genetics, Epigenetics and Diagnostics
- Surgical Threshold Updates and Absolute Cutoffs for FAA, BAV, Marfan, LDS
- New gene discoveries for HTAD
- Therapeutics/Management Updates including Pharmacotherapy, Imaging Surveillance and Genetic Risk
- Emergency Department Outcomes: Recognition and Management for Aortic Dissection
- Mental Health Studies for HTAD
- Exercise Studies, what are we learning?
IRAD/GenTAC Abstract Guidelines
- Abstracts must be submitted electronically and will be due by April 15, 2024. Link for abstract submissions
- Abstract must be written in English.
- The names of the authors should be listed in the following order: Last name, first name, degree, department, institution, city, state, and country.
- The presenting author’s name should be underlined.
- The abstract should be a maximum of 300 words and include the following sections: introduction, objectives, materials and methods, results and conclusion.
- Please use 12 pt. Arial, single spaced, and 1” margins.
- Abstracts must be only 1 page and have no diagrams.
- There is no limit to the number of abstracts a presenter can submit.
- All authors will receive notification by May 1 for poster presentation.
- For inquiries, please contact jgrima@marfan.org.
Meeting Chairs:
Kim Eagle, MD
University of Michigan
Bart Loeys, MD, PhD, Co-Chair
University of Antwerp
Maral Ouzounian, MD
University of Toronto
William Ravekes, MD
Johns Hopkins Hospital
Marion Hofmann-Bowman, MD
University of Michigan
Josephine Grima, PhD
The Marfan Foundation
